Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...

Brace yourselves, Ozempic and Zepound. Eli Lilly just released a jaw-dropping sneak peek from the final phases of testing for ...

The City of Huntsville has taken another step toward bringing pharmaceutical giant Eli Lilly’s $6 billion facility to the ...

Eli Lilly and Company has delivered significant positive developments this week, though its shares experienced a minor pullback in Wednesday's trading sessio ...

Though it hasn't even wrapped up clinical trials, the weight loss drug retatrutide already has a cult following.

Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...

The new "triple agonist" weight loss medication called retatrutide can help people lose an average of 28.7 percent of ...

In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...